Document Detail


The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes.
MedLine Citation:
PMID:  14555237     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PEA-15 is a small protein (15 kDa) that was first identified as an abundant phosphoprotein in brain astrocytes [Araujo et al., J Biol Chem 1993;268(8):5911-20], and subsequently shown to be widely expressed in different tissues and highly conserved among mammals [Estelles et al., J Biol Chem 1996;271(25):14800-6; Danziger et al., J Neurochem 1995;64(3):1016-25]. It is composed of a N-terminal death effector domain and a C-terminal tail of irregular structure. PEA-15 is regulated by multiple calcium-dependent phosphorylation pathways that account for its different forms: a non-phosphorylated form in equilibrium with a mono and a biphosphorylated variety. This already suggested that PEA-15 may play a major role in signal integration. Accordingly, it has been demonstrated to modulate signaling pathways that control apoptosis and cell proliferation. In particular, PEA-15 diverts astrocytes from TNFalpha-triggered apoptosis and regulates the actions of the ERK MAP kinase cascade by binding to ERK and altering its subcellular localization. The three-dimensional structure of PEA-15 has been modelized and recently determined using NMR spectroscopy, and may help to understand the various functions played by the protein through its molecular interactions.
Authors:
François Renault; Etienne Formstecher; Isabelle Callebaut; Marie-Pierre Junier; Hervé Chneiweiss
Related Documents :
15082127 - Activation of extracellular signal-regulated protein kinase in dorsal horn neurons in t...
25088577 - Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast ce...
11597767 - Group i metabotropic glutamate receptor activation increases phosphorylation of camp re...
23332287 - Preclinical rationale for pi3k/akt/mtor pathway inhibitors as therapy for epidermal gro...
23241357 - C-jun n-terminal kinase activation contributes to reduced connexin43 and development of...
18242697 - Tailoring tyrosine kinase inhibitor therapy to tackle specific bcr-abl1 mutant clones.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Biochemical pharmacology     Volume:  66     ISSN:  0006-2952     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-13     Completed Date:  2003-11-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1581-8     Citation Subset:  IM    
Affiliation:
INSERM U114, Collège de France, 11 Place Marcelin Berthelot, 75231 Paris Cedex 05, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Apoptosis / physiology*
Astrocytes / cytology*,  metabolism
Cell Cycle / physiology
Humans
Intracellular Signaling Peptides and Proteins
Phosphoproteins / genetics,  physiology*
Transcription, Genetic
Tumor Necrosis Factor-alpha / physiology
Chemical
Reg. No./Substance:
0/Intracellular Signaling Peptides and Proteins; 0/PEA15 protein, human; 0/Phosphoproteins; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Apoptosis in male germ cells in response to cyclin A1-deficiency and cell cycle arrest.
Next Document:  Targeting apoptosis in acute tubular injury.